Drug intelligence / Profile preview

topical dissolved oxygen

Development stage: Phase 2
Lead developer: Aria Aesthetics
Modality: Small Molecules
Administration: Topical

Overview

Topical dissolved oxygen is a cosmeceutical product being evaluated for its role in ameliorating visible signs of photodamage and assessing overall skin tolerability. It is applied topically, with concentrations of 0.5% and 0.25% being studied in clinical trials. The product is developed by Aria Aesthetics Inc.

Brand names: Aria Oxygen
Other names: Topical oxygen

Beyond the preview

Go deeper on topical dissolved oxygen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on topical dissolved oxygen.

Explore the full profile